恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

已收盘 07-30 16:08:22

57.400

-0.900

-1.54%

最高59.300	最低56.200	成交量418.34万
今开58.750	昨收58.300	日振幅5.32%
总市值3,810亿	流通市值148.09亿	总股本66.37亿
成交额2.41亿	换手率1.62%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":57.4,"timestamp":1785398902002,"preClose":58.3,"halted":0,"volume":4183390,"delay":0,"changeRate":-0.015437392795883338,"floatShares":258000000,"shares":6637000000,"eps":1.3706008597157293,"marketStatus":"已收盘","change":-0.9,"latestTime":"07-30 16:08:22","open":58.75,"high":59.3,"low":56.2,"amount":240887854,"amplitude":0.053173,"askPrice":57.45,"askSize":20000,"bidPrice":57.4,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":1.4178958815851403,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":58.3,"dividendRate":0.004035,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":1.82836,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.65,"timestamp":1785394800000,"preClose":53.89,"halted":0,"volume":73587800,"delay":0,"premium":"-9.57"}},"requestUrl":"/m/hq/s/01276/wiki","defaultTab":"wiki","newsList":[{"id":"1107059414","title":"异动解读｜恒瑞医药盘中下跌3.17%，制药板块整体承压拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1107059414","media":"行情直击","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107059414?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:29","pubTimestamp":1785382159,"startTime":"0","endTime":"0","summary":"7月30日，恒瑞医药(01276.HK)盘中下跌3.17%，报56.45港元，成交额9835.83万港元。尽管公司近日密集发布利好——自主研发的国内首个长效胰岛素类似物舒地胰岛素注射液获批上市、HER3靶向ADC瑞康芦泽妥塔单抗上市许可申请获受理，同时获Capital Group增持75.22万股，但股价仍随行业整体走弱而下行。当日制药板块普遍承压，中国生物制药跌5.16%、凯莱英跌7.82%、石药集团跌3.31%、翰森制药跌2.45%，行业性抛压明显，恒瑞医药未能独善其身。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"恒瑞医药盘中下跌3.17%，制药板块整体承压拖累股价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655684807","title":"恒瑞医药获The Capital Group Companies, Inc.增持75.22万股 每股作价约56.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655684807","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655684807?lang=zh_cn&edition=full","pubTime":"2026-07-30 08:15","pubTimestamp":1785370500,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，7月24日，The Capital Group Companies， Inc．增持恒瑞医药（01276）75.22万股，每股作价56.7648港元，总金额约为4269.85万港元。增持后最新持股数目约为2369.78万股，持股比例为9.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-30/doc-inikptat5288001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1580142542.USD","LU2097828805.USD","BK1191","LU2580892862.HKD","LU0405327148.USD","LU1969619763.USD","01276","LU2097828557.USD","LU1255011170.USD","BK0012","LU2097828474.EUR","LU2148510915.USD","LU1781817850.SGD","LU0359201885.HKD","LU1997245094.SGD","BK0028","LU1997245177.USD","LU2328871848.SGD","LU1820825898.SGD","EWH","LU2097828714.EUR","BK0196","LU2580892789.USD","LU1023057109.AUD","LU1064130708.USD","LU2289578879.USD","BK0060","LU1655091616.SGD","LU1328615791.USD","LU1997244956.HKD","LU2495084118.USD","LU2543165471.USD","LU2097828631.EUR","BK0188","BK0239","LU0359201612.USD","600276","LU0359202008.SGD","LU0405327494.USD","BK0183","LU1146622755.USD","LU2488822045.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178930666","title":"恒瑞医药（01276）自主研发长效胰岛素获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1178930666","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178930666?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:16","pubTimestamp":1785334580,"startTime":"0","endTime":"0","summary":"2026年7月29日，江苏恒瑞医药股份有限公司公告称，公司收到国家药品监督管理局批准，旗下1类治疗用生物制品舒地胰岛素注射液获准上市，为国内首个自主研发的长效胰岛素类似物。此次上市批准主要基于两项关键Ⅲ期临床试验，结果显示在中国T2DM患者中，舒地胰岛素在血糖控制上与甘精胰岛素整体相当，且夜间低血糖风险更低。公司提醒，药品上市后生产和销售仍可能面临不确定性，请投资者注意风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655189601","title":"恒瑞医药(01276.HK)自主研发的 1 类治疗用生物制品舒地胰岛素注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2655189601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655189601?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:16","pubTimestamp":1785334572,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","LU0359202008.SGD","LU0359201885.HKD","LU1023057109.AUD","LU0359201612.USD","LU2543165471.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126582745","title":"恒瑞医药 (01276)：HER3 靶向 ADC 瑞康芦泽妥塔单抗获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1126582745","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126582745?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:11","pubTimestamp":1785334296,"startTime":"0","endTime":"0","summary":"2026年7月29日，恒瑞医药  发布公告称，其全资子公司苏州盛迪亚生物医药有限公司提交的注射用瑞康芦泽妥塔单抗上市许可申请已获国家药品监督管理局受理，受理号为 CXSS2600111。该产品剂型为注射剂，拟用于经表皮生长因子受体酪氨酸激酶抑制剂治疗后进展的 EGFR 基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌成人患者。结果显示，相较于含铂双药化疗，瑞康芦泽妥塔单抗显著延长患者无进展生存期。目前全球尚无获批针对 NSCLC 的 HER3 靶向 ADC。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135511732","title":"恒瑞医药（01276）注射用HRS5580获批开展II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1135511732","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135511732?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:10","pubTimestamp":1785334246,"startTime":"0","endTime":"0","summary":"恒瑞医药7月29日公告称，其子公司福建盛迪医药有限公司已收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用HRS5580获准开展II期临床试验。受理号为CXHL2600457，审批结论显示该项目于2026年4月17日受理并符合药品注册的有关要求。公告披露，截至目前，HRS5580项目累计研发投入约5,770万元。恒瑞医药将按法规推进项目，并及时披露后续进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655896907","title":"恒瑞医药(01276.HK)：注射用HRS5580获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2655896907","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655896907?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:02","pubTimestamp":1785333750,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0359202008.SGD","LU0359201885.HKD","LU1023057109.AUD","LU0359201612.USD","LU2543165471.USD","BK1191","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860979","title":"恒瑞医药(600276.SH)：舒地胰岛素注射液获批上市 该产品是中国首个自主研发的长效胰岛素类似物","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860979","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655860979?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:14","pubTimestamp":1785327289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，公司近日，公司收到国家药品监督管理局的通知，批准公司自主研发的1类治疗用生物制品舒地胰岛素注射液上市，用于治疗成人2型糖尿病。舒地胰岛素注射液是公司自主研发的基础长效胰岛素，具备起效平稳、药效维持时间长和产生夜间性低血糖风险低等优点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU2543165471.USD","LU2580892862.HKD","LU1997245094.SGD","LU2097828631.EUR","LU2097828714.EUR","LU2488822045.USD","IPOS","LU1997244956.HKD","LU0405327148.USD","BK1191","LU1580142542.USD","LU0359201612.USD","LU2097828474.EUR","LU2328871848.SGD","LU1064131003.USD","LU0405327494.USD","LU2289578879.USD","BK0012","BK0060","LU1328615791.USD","LU0359202008.SGD","01276","LU1655091616.SGD","BK0239","LU2148510915.USD","LU1997245177.USD","LU1820825898.SGD","LU1064130708.USD","LU2097828557.USD","LU1255011170.USD","600276","BK0183","BK0196","LU2580892789.USD","LU1781817850.SGD","LU2097828805.USD","BK0188","LU2495084118.USD","LU1969619763.USD","LU1023057109.AUD","BK0028","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867677","title":"A股公告精选 | 国内首个，恒瑞医药(600276.SH)自主研发的长效糖尿病治疗药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867677","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655867677?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:41","pubTimestamp":1785325291,"startTime":"0","endTime":"0","summary":"恒瑞医药公告称，公司收到国家药监局通知，批准自主研发的1类治疗用生物制品舒地胰岛素注射液上市，该产品是中国首个自主研发的长效胰岛素类似物，用于治疗成人2型糖尿病。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260729/20260729194215_21643.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260729/20260729194215_21643.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0012","LU2097828557.USD","LU1580142542.USD","LU2328871848.SGD","BK0239","BK1191","600276","LU0359201885.HKD","LU2097828474.EUR","LU2580892789.USD","LU1064131003.USD","LU1997244956.HKD","LU2097828631.EUR","LU1997245094.SGD","LU1655091616.SGD","159982","BK0028","LU2097828714.EUR","LU2488822045.USD","LU2495084118.USD","LU0359202008.SGD","LU2148510915.USD","LU1023057109.AUD","LU1969619763.USD","LU1781817850.SGD","LU2580892862.HKD","LU1820825898.SGD","LU1997245177.USD","BK0183","BK0196","399300","LU1146622755.USD","01276","LU0405327494.USD","LU0405327148.USD","IPOS","LU2289578879.USD","LU0359201612.USD","LU2097828805.USD","BK0060","LU1328615791.USD","BK0188","LU1255011170.USD","LU1064130708.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867110","title":"The Capital Group Companies, Inc.增持恒瑞医药(01276.HK)75.22万股 每股作价约56.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867110","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655867110?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:17","pubTimestamp":1785323870,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2543165471.USD","BK1191","LU0359202008.SGD","LU1023057109.AUD","LU0359201612.USD","01276","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655442866","title":"恒瑞医药：子公司注射用HRS5580获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2655442866","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655442866?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:02","pubTimestamp":1785319320,"startTime":"0","endTime":"0","summary":"7月29日，恒瑞医药（600276/01276）发布公告，子公司福建盛迪医药有限公司收到国家药监局核准签发关于注射用HRS5580的药物临床试验批准通知书，将于近期开展临床试验。注射用HRS5580申请的适应症为预防术后恶心和呕吐，以及联合盐酸帕洛诺司琼注射液用于预防术后恶心和呕吐。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825197461.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825197461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","LU0359201612.USD","BK0012","01276","LU0405327494.USD","LU2097828714.EUR","LU2097828474.EUR","LU1997245177.USD","LU2328871848.SGD","LU2488822045.USD","LU1255011170.USD","LU2148510915.USD","LU2097828805.USD","LU1580142542.USD","LU1023057109.AUD","LU1655091616.SGD","LU1969619763.USD","LU1997245094.SGD","BK0188","LU2543165471.USD","LU2580892789.USD","BK0183","LU0405327148.USD","BK1191","LU2495084118.USD","BK0196","LU1820825898.SGD","LU2097828631.EUR","BK0060","LU2580892862.HKD","LU1997244956.HKD","BK0028","LU2097828557.USD","LU0359202008.SGD","600276","LU2289578879.USD","LU1064131003.USD","LU1781817850.SGD","LU1328615791.USD","LU1146622755.USD","LU0359201885.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655865496","title":"恒瑞医药(600276.SH)：注射用瑞康芦泽妥塔单抗上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655865496","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655865496?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:55","pubTimestamp":1785318936,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司注射用瑞康芦泽妥塔单抗(注射用SHR-A2009)的药品上市许可申请获国家药监局受理。拟定适应症(或功能主治)：本品用于经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成人患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","LU2097828714.EUR","LU0359201885.HKD","LU1655091616.SGD","LU2580892862.HKD","LU1997245094.SGD","LU2495084118.USD","LU2148510915.USD","01276","LU1064130708.USD","LU2097828474.EUR","BK0239","LU1255011170.USD","LU2097828557.USD","BK0028","LU0359201612.USD","LU1023057109.AUD","BK0188","BK0012","LU2097828805.USD","LU2580892789.USD","600276","LU1820825898.SGD","LU1580142542.USD","LU1997244956.HKD","LU2543165471.USD","BK1191","LU2289578879.USD","LU1328615791.USD","LU1064131003.USD","LU1969619763.USD","LU1146622755.USD","LU2488822045.USD","LU0405327148.USD","BK0060","LU2097828631.EUR","IPOS","LU2328871848.SGD","LU1781817850.SGD","LU0359202008.SGD","LU1997245177.USD","BK0196","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655857023","title":"智通AH统计|7月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2655857023","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655857023?lang=zh_cn&edition=full","pubTime":"2026-07-29 16:15","pubTimestamp":1785312911,"startTime":"0","endTime":"0","summary":"东北电气0.2332.251058.80%157.23%浙江世宝3.75013.28324.27%-28.09%中石化油服0.6402.2312.50%-3.82%弘业期货2.1907.52311.42%27.20%安德利果汁17.75056.15278.93%-28.95%复旦张江2.4007.22260.42%-13.84%晨鸣纸业0.6701.96250.75%-17.76%长飞光纤光缆102.800300249.55%55.28%南京熊猫电子股份3.4009.9248.82%12.76%凯盛新能2.3406.73244.44%-10.01%. 东北电气0.2332.251058.80%157.23%广合科技93.100163109.71%57.99%长飞光纤光缆102.800300249.55%55.28%剑桥科技70.950149.8152.90%36.50%大族数控94.650236.31199.05%32.11%胜宏科技178.30023155.18%29.30%国恩科技31.76047.7680.13%27.56%弘业期货2.1907.52311.42%27.20%广和通7.52020.3223.40%24.32%鼎泰高科286.000398.3766.84%23.94%. 备注：以上数据由智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；偏离值为当前溢价率与该股过去30天平均溢价率的差值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02715","06613","01989","BK1562","06031","03328","82318","HPAD.SI","02476","02768","00991","03145","03678","LU0882747503.HKD","03143","02691","01033","02359","LU0449509016.USD","01057","03750","601318","06869","399300","02218","159982","06166","02208","01108","03986","02465","02318","00638","03200","PAImain","LU2226246903.HKD","00042","01276","01349","01377","00916","01812","06680","02338","PNGAY","EWH","00553","00300","03968"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654074838","title":"恒瑞医药在浙江成立新公司 注册资本5000万","url":"https://stock-news.laohu8.com/highlight/detail?id=2654074838","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654074838?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:36","pubTimestamp":1785224160,"startTime":"0","endTime":"0","summary":"南方财经7月28日电，天眼查App显示，近日，浙江恒瑞医药有限公司成立，法定代表人为戴洪斌，注册资本5000万人民币，经营范围含医学研究和试验发展、药品批发、药品零售、药品委托生产等。股东信息显示，该公司由江苏恒瑞医药股份有限公司全资持股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823485913.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823485913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997244956.HKD","LU0405327148.USD","BK0183","LU2580892862.HKD","LU1064130708.USD","BK0028","LU0359202008.SGD","LU1023057109.AUD","01276","LU1997245177.USD","LU0359201612.USD","LU1820825898.SGD","LU0359201885.HKD","LU2097828805.USD","LU2328871848.SGD","LU1997245094.SGD","LU2097828557.USD","LU1146622755.USD","LU2097828474.EUR","LU2495084118.USD","BK0188","LU1969619763.USD","LU2097828714.EUR","LU1655091616.SGD","600276","BK0012","BK0196","LU1580142542.USD","BK1191","LU2097828631.EUR","BK0239","LU1064131003.USD","LU2148510915.USD","LU2488822045.USD","LU2543165471.USD","LU1328615791.USD","BK0060","LU2289578879.USD","LU0405327494.USD","LU1781817850.SGD","LU1255011170.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","LU0196878994.USD","LU2399975544.HKD","01548","01801","02162","02269","LU1720050803.USD","BK1521","HK0000320223.HKD","LU0588546209.SGD","LU1813983027.USD","06996","09926","LU2097828714.EUR","03329","LU2328871848.SGD","159938","LU2476274308.USD","01276","02268","BK1219","06821","LU1880383366.USD","LU0348783233.USD","LU0856984785.SGD","HK0000165453.HKD","09996","00013","BK1587","02273","03759","02596","03692","06078","01952","06160","LU0634319403.HKD","KCE","09966","01951","01177","09939","01530","LU0417516571.SGD","02096","LU2039709279.SGD","06990","KURE","LU0572944931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109637160","title":"恒瑞医药（01276）HRS-1780片获准开展Ⅱ/Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1109637160","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109637160?lang=zh_cn&edition=full","pubTime":"2026-07-27 23:01","pubTimestamp":1785164472,"startTime":"0","endTime":"0","summary":"2026年7月27日，江苏恒瑞医药股份有限公司公告称，其子公司山东盛迪医药有限公司已于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意HRS-1780片开展Ⅱ/Ⅲ期临床试验。国家药监局于2026年4月24日受理该申请，经审查后批准其进入Ⅱ/Ⅲ期临床阶段。截至目前，HRS-1780片相关项目累计研发投入约1.00亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654498630","title":"恒瑞医药(01276.HK)：HRS-1780片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654498630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654498630?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:58","pubTimestamp":1785164298,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023057109.AUD","BK1191","01276","LU0359202008.SGD","LU0359201885.HKD","LU2543165471.USD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197107353","title":"恒瑞医药（01276）五项抗肿瘤管线同时获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1197107353","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197107353?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:55","pubTimestamp":1785164147,"startTime":"0","endTime":"0","summary":"2026年7月27日，恒瑞医药公告称，其子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，涉及 SHR-4610 注射液、注射用 SHR-1826、注射用 SHR-A2009、注射用瑞康曲妥珠单抗及 SHR-8068 注射液共五款创新药物，受理号分别为 CXSL2600425、CXSL2600418、CXSL2600422、CXSL2600426、CXSL2600419。根据批件，上述药物于2026年4月17日被受理，经审查符合药品注册要求，获准开展临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135904501","title":"恒瑞医药（01276）SHR-4375注射液获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1135904501","media":"公告速递","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135904501?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:55","pubTimestamp":1785164136,"startTime":"0","endTime":"0","summary":"2026年7月27日，恒瑞医药公告称，其自主研发的SHR-4375注射液获美国食品药品监督管理局授予孤儿药资格，适应症为胰腺癌。该认定系依据美国《联邦食品、药品和化妆品法案》第526条作出。恒瑞医药提醒投资者，SHR-4375后续仍需与FDA就临床试验及注册事宜沟通，能否最终获批上市存在不确定性；若同适应症的同类药物抢先获批，需进一步证明其临床优效性，否则可能失去孤儿药相关政策支持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013089","title":"恒瑞医药：SHR-4375注射液治疗胰腺癌适应症获FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013089","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654013089?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:53","pubTimestamp":1785142380,"startTime":"0","endTime":"0","summary":"7月27日，恒瑞医药（600276/01276）发布公告，公司产品SHR-4375注射液用于治疗胰腺癌适应症获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定。此资格将使公司在产品研发、注册及商业化等方面享受美国的政策支持。SHR-4375注射液是公司自主研发的抗体药物偶联物，已推进至国内临床试验的Ⅱ期阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273822155855.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273822155855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU2097828714.EUR","LU1969619763.USD","LU1655091616.SGD","BK0060","BK1191","LU0405327148.USD","LU1820825898.SGD","LU1023057109.AUD","LU1255011170.USD","LU1997245094.SGD","BK4585","600276","LU1997245177.USD","LU2495084118.USD","LU2289578879.USD","01276","LU1328615791.USD","LU2097828474.EUR","LU0359201612.USD","BK0188","LU2580892862.HKD","BK0183","LU1064131003.USD","LU2580892789.USD","BK4588","BK0012","LU0359202008.SGD","LU2543165471.USD","LU1580142542.USD","LU1146622755.USD","LU2097828805.USD","LU2488822045.USD","LU2328871848.SGD","LU1781817850.SGD","LABU","LU0405327494.USD","LU2097828557.USD","LU1064130708.USD","BK0028","BK0196","LU0359201885.HKD","BK0239","LU2097828631.EUR","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0026},{"period":"3month","weight":-0.1031},{"period":"6month","weight":-0.1453},{"period":"1year","weight":-0.2848},{"period":"ytd","weight":-0.1789}],"compareEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.0111},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}